Cure My Disease

Don't miss your cure!

 Log in / Sign up

Second chance: vyxeos targets tough leukemia after standard chemo fails

NCT ID NCT04049539

Recruiting now Disease control Sponsor: Ohio State University Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a drug called Vyxeos in adults with acute myeloid leukemia (AML) whose cancer did not go away after standard chemotherapy. Vyxeos combines two chemo drugs inside a tiny fat bubble (liposome) to deliver them more effectively. The trial will check for side effects and see how many patients achieve remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Vyxeos (a liposome containing two chemotherapy drugs: cytarabine and daunorubicin)
What this could lead to
If it works, this could offer a treatment option for people with acute myeloid leukemia who did not get better after standard chemotherapy.
What could go wrong
This is a small, early-phase trial (Phase 1/2) with only 28 participants. The drug may not work for everyone, and side effects like infections, heart problems, or bleeding are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS PERSISTENT DISEASE REFRACTORY ACUTE MYELOID LEUKEMIA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

  • UC Davis Comprehensive Cancer Center

    RECRUITING

    Sacramento, California, 95817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.